BMS expands Massachusetts presence with cell therapy manufacturing facility

SourcePharma Manufacturing
Date Published02/23/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Bristol Myers Squibb
Type of work Manufacturing
Reshoring category:Reshoring
Year reshoring announced:2021
Year reshoring implemented or to be implemented:2021
Domestically, the work will be done:In-house
City reshored to:Devens
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredclinical transformative cell therapies
What domestic positive factors made reshoring more attractive?Infrastructure, Proximity to customers/market, Under-utilized capacity, Other, import replacement
Find Reshoring Articles